Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731002 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT01731002: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT01731002 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 224 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01731002, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
Primary Outcome
The primary efficacy endpoint was the mean IOP across subjects within treatment group on each day at each post-treatment timepoint. IOP was measured at 0800, 1000, and 1600 hours on days 0, 14, and 28. IOP was also measured at 0800 hours on Day 7 and follow-up days 29 and 30.
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Latanoprost ophthalmic solution 0.005%
- DRUG AR-13324 Ophthalmic Solution 0.01%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01731002 record still lists
NCT01731002 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 3 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT01731002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01731002 about?
NCT01731002 is a clinical study titled "Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure". Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
What is the current status of trial NCT01731002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2012-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01731002?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), Latanoprost ophthalmic solution 0.005% (DRUG), AR-13324 Ophthalmic Solution 0.01% (DRUG).
Who is sponsoring clinical trial NCT01731002?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01731002's enrollment target sits among peer trials
224 269th of 2000 higher than 1,727 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia